This inventor holds 2 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Chemokine Therapeutics Corporation, The University of British Columbia. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 7 
2 out of 962 
Years Active: 2008
Title: Johanne Cashman: Innovator in Hematopoietic Cell Treatments
Introduction
Johanne Cashman is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of hematopoietic cell treatments, holding two patents that showcase her innovative work. Her research focuses on the use of CXCR4 antagonists and agonists in promoting and regulating hematopoietic cell functions.
Latest Patents
Johanne's latest patents include a treatment involving CXCR4 antagonists for hematopoietic cells. This invention outlines how CXCR4 antagonists can be utilized to enhance the multiplication, self-renewal, and proliferation of progenitor or stem cells. Additionally, her patent on CXC chemokine receptor 4 agonist peptides describes methods for reducing the rate of hematopoietic cell multiplication. These methods involve administering effective amounts of CXCR4 agonists to hematopoietic stem and progenitor cells, either in vitro or in vivo, to assist patients requiring stem cell transplantation.
Career Highlights
Throughout her career, Johanne has worked with notable organizations, including Chemokine Therapeutics Corporation and the University of British Columbia. Her work in these institutions has allowed her to advance her research and contribute to the scientific community significantly.
Collaborations
Johanne has collaborated with esteemed colleagues such as Christopher R. Tudan and Ahmed Merzouk. These partnerships have further enriched her research and innovation in the field.
Conclusion
Johanne Cashman is a trailblazer in the realm of hematopoietic cell treatments, with her patents reflecting her dedication to advancing medical science. Her innovative approaches have the potential to impact the treatment of patients requiring stem cell therapies significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile